Shares of Zogenix, Inc. (NASDAQ:ZGNX) have been assigned a consensus rating of “Buy” from the twelve ratings firms that are covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and ten have issued a buy recommendation on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $73.00.

ZGNX has been the topic of several research reports. Mizuho reiterated a “buy” rating and set a $69.00 price objective on shares of Zogenix in a report on Thursday, August 9th. BidaskClub downgraded shares of Zogenix from a “buy” rating to a “hold” rating in a research report on Friday, August 10th. Stifel Nicolaus assumed coverage on shares of Zogenix in a research report on Wednesday, August 15th. They set a “buy” rating and a $69.00 target price for the company. LADENBURG THALM/SH SH assumed coverage on shares of Zogenix in a research report on Thursday, August 23rd. They set a “buy” rating and a $71.00 target price for the company. Finally, B. Riley assumed coverage on shares of Zogenix in a research report on Friday, September 7th. They set a “buy” rating and a $116.00 target price for the company.

In other Zogenix news, EVP Gail M. Farfel sold 6,961 shares of the company’s stock in a transaction dated Thursday, October 4th. The shares were sold at an average price of $43.23, for a total value of $300,924.03. Following the completion of the sale, the executive vice president now directly owns 14,104 shares of the company’s stock, valued at approximately $609,715.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Erle T. Mast sold 1,468 shares of the company’s stock in a transaction dated Monday, November 26th. The stock was sold at an average price of $42.08, for a total transaction of $61,773.44. Following the completion of the sale, the director now directly owns 3,027 shares of the company’s stock, valued at $127,376.16. The disclosure for this sale can be found here. Insiders own 5.00% of the company’s stock.

Hedge funds have recently modified their holdings of the business. BlueMountain Capital Management LLC bought a new stake in Zogenix in the 2nd quarter worth about $104,000. SG Americas Securities LLC bought a new stake in Zogenix in the 3rd quarter worth about $109,000. FNY Investment Advisers LLC grew its position in Zogenix by 3,900.0% in the 3rd quarter. FNY Investment Advisers LLC now owns 3,000 shares of the company’s stock worth $148,000 after purchasing an additional 2,925 shares in the last quarter. Prudential Financial Inc. bought a new stake in Zogenix in the 3rd quarter worth about $219,000. Finally, Public Employees Retirement Association of Colorado bought a new stake in Zogenix in the 3rd quarter worth about $226,000.

Shares of NASDAQ ZGNX traded down $0.26 during trading on Friday, hitting $43.61. 723,785 shares of the company traded hands, compared to its average volume of 621,260. Zogenix has a fifty-two week low of $33.42 and a fifty-two week high of $62.75. The firm has a market capitalization of $1.84 billion, a P/E ratio of -10.85 and a beta of 1.84.

Zogenix (NASDAQ:ZGNX) last announced its quarterly earnings data on Thursday, November 8th. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.20). During the same quarter in the previous year, the business posted ($1.68) EPS. Sell-side analysts forecast that Zogenix will post -3.84 earnings per share for the current fiscal year.

Zogenix Company Profile

Zogenix, Inc, a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. Its lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome.

Read More: Diversification

Analyst Recommendations for Zogenix (NASDAQ:ZGNX)

Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.